Drug Regulation has been the focus of several recent policy reform efforts in India, starting
with the Mashelkar Committee Report in 2003 to the most recent report of the Ranjit Roy
Chaudhary Committee in 2013. Nevertheless, the regulatory structure continues to be
plagued with several structural challenges, including issues related to regulatory
harmonisation between the centre and the states, access to regulatory resources,
transparency, which have undermined the general effectiveness of the regulatory system. At
the juncture when the Drugs and Cosmetics (Amendment) Bill, 2015 to amend the Drugs and
Cosmetic Act, 1940, is expected to overhaul the drug regulation, this study, the first of its
kind, evaluates the administrative structure and functions of drug regulatory authorities at
both the federal and state level along with comparative perspectives on similar challenges
from other international jurisdictions. Through legal and policy analysis, supported by
stakeholder interactions, this study not only provides a systematic analysis of the current
challenges, along with actionable policy recommendations and suggests possible means for
their operationalisation.